Barclays: Johnson & Johnson's Q3 Could Be 'High Water Mark' By: Benzinga via Benzinga October 15, 2014 at 16:42 PM EDT Johnson & Johnson's (NYSE: JNJ) new hepatitis C drug Olysio helped it beat third quarter Street views, but an analyst ... Read More >> Related Stocks: Gilead Sciences Johnson & Johnson